AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11339442
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg folic acid daily
Trial: 11339442
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg folic acid daily
Trial: 9148986
Drug: Diagnostic peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic peritoneal lavage (DPL) with 1 L crystalloid
Trial: 8131364
Drug: Natural surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural surfactant extract (prophylactic administration)
Trial: 8131364
Drug: Natural surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural surfactant extract (administration to infants with moderate to severe RDS)
Trial: 31352308
Drug: High-risk drug
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk drug use (methamphetamine, cocaine, opioids)
Trial: 26741306
Drug: Anterior mini-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterior mini-implant group (AMG)
Trial: 26741306
Drug: Posterior mini-implant
RxNorm normalized name: posterior pituitary hormones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posterior mini-implant group (PMG)
Trial: 22527337
Drug: Cement injection
RxNorm normalized name: Cement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cement injection stem (secondary cementing technique)
Trial: 19326803
Drug: Multidisciplinary quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary quality improvement program to reduce RFOs, including education programs, team training, simulation videos, and daily reminders.
Trial: 11075845
Drug: Intranasal civamide
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal civamide 20 microg
Trial: 11075845
Drug: Intranasal civamide
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal civamide 150 microg
Trial: 3732891
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (total parenteral nutrition and steroids)
Trial: 31780130
Drug: iCBT (internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-delivered cognitive behavioural therapy)
Trial: 16291600
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg etoricoxib once daily
Trial: 16291600
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg rofecoxib once daily
Trial: 3710013
Drug: Sucrose diet
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose diet (45 g of sucrose replacing 45 g of complex carbohydrate)
Trial: 29803703
Drug: ALPS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALPS treatment group
Trial: 17318503
Drug: Aripiprazole 15
RxNorm normalized name: aripiprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 15 mg daily
Trial: 24359506
Drug: Risperidone 4
RxNorm normalized name: risperidone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 4 mg daily
Trial: 22260988
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (one, two, or three doses at 1 month, 2 months, or 6 months intervals)
Trial: 22260988
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (two or three doses)
Trial: 22260988
Drug: 4CMenB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4CMenB vaccine (second or third doses)
Trial: 24699554
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) injection
Trial: 24699554
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) injection
Trial: 17904629
Drug: Treatment (phone-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (phone- and mail-based physical activity maintenance intervention)
Trial: 12534644
Drug: Erythromycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (600 mg ethylsuccinate ester, three oral doses on day 1 and two doses on day 2)
Trial: 3883182
Drug: Omeprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (30 mg per day)
Trial: 20215456
Drug: Intensive glycemia
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemia treatment
Trial: 25082605
Drug: Intervention (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention (monthly telephone interviews for six months)
Trial: 11257953
Drug: Droperidol 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 1.25 mg every 8 h
Trial: 11257953
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg every 8 h
Trial: 3346792
Drug: Metoclopramide (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.125 mg/kg intravenous dose)
Trial: 3346792
Drug: Metoclopramide (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.125 mg/kg four times a day for 24 hours)
Trial: 29769088
Drug: Randomisation to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomisation to one of two comparable drugs during a routine consultation
Trial: 29769088
Drug: Electronic system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic system randomising a patient to drug A or drug B
Trial: 25881751
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg test formulation (one 400-mg tablet)
Trial: 25881751
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg reference formulation (four 100-mg tablets)
Trial: 24666765
Drug: Tadalafil (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (2.5 mg titrated to 5 mg or 5 mg)
Trial: 24666765
Drug: Tadalafil (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (2.5 mg titrated to 5 mg or 5 mg) with IIEF-EF score ≥ 26
Trial: 24666765
Drug: Tadalafil (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (2.5 mg titrated to 5 mg or 5 mg) achieving minimal clinically important difference in IIEF-EF score
Trial: 11798515
Drug: Amifostine at
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amifostine at 740 mg/m(2)
Trial: 9093983
Drug: High-volume nasogastric
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume nasogastric balanced polyethylene glycol electrolyte lavage (20 ml/kg/h) until the effluent was clear (n = 15)
Trial: 9093983
Drug: Low-volume sodium
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume sodium phosphate solution (22.5-45 ml) separated by oral fluid intake (n = 14)
Trial: 2282101
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (5 g of n‐3 fatty acids daily for 30 days)
Trial: 2282101
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 wheat germ oil capsules daily for 30 days)
Trial: 7023599
Drug: Primary closure
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary closure with topical ampicillin powder
Trial: 26398887
Drug: Ezetimibe plus
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe plus high-potency statin (10mg atorvastatin or 1mg pitavastatin)
Trial: 26398887
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose statin (20mg atorvastatin or 2mg pitavastatin)
Trial: 25969561
Drug: 1 or
RxNorm normalized name: G-1 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 or 2 doses of inactivated hepatitis A vaccine (Healive)
Trial: 25969561
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of live attenuated hepatitis A vaccine (Biovac)
Trial: 21148807
Drug: initial treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: initial treatment group assignment
Trial: 21148807
Drug: antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antidepressant medication use during follow-up
Trial: 7903921
Drug: Methotrexate, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, 15 mg/wk
Trial: 1095965
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg S‐adenosylmethionine (SAMe) plus 6000 gamma/day of Vitamin B12
Trial: 25498469
Drug: Wheat bran
RxNorm normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat bran extract (WBE) 10 g/d
Trial: 25498469
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 10 g/d)
Trial: 23527300
Drug: CCX282-B 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX282-B 500 mg once daily
Trial: 23527300
Drug: CCX282-B 250
RxNorm normalized name: amphotericin B 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX282-B 250 mg once daily
Trial: 23527300
Drug: CCX282-B 250
RxNorm normalized name: amphotericin B 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCX282-B 250 mg twice daily
Trial: 12921628
Drug: Short-term lactulose
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term lactulose (15 - 90 ml/d for 8 weeks)
Trial: 12921628
Drug: Long-term lactulose
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term lactulose (15 - 90 ml/d for 24 weeks)
Trial: 10699232
Drug: Verapamil-Magnesium Oxide
RxNorm normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Verapamil-Magnesium Oxide (V-M) combination
Trial: 10699232
Drug: Verapamil-Placebo (V-P)
RxNorm normalized name: P.V.P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil-Placebo (V-P) combination
Trial: 9088585
Drug: Timolol 10
RxNorm normalized name: timolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 10 mg twice daily for 14 days
Trial: 7655642
Drug: GH in
RxNorm normalized name: High incidence antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH in daily injections (0.125 IU.kg‐1. week‐1 for the first 4 weeks and subsequently 0.25 IU.kg‐1. week‐1)
Trial: 2660871
Drug: Sultamicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sultamicillin (500 mg every 12 h)
Trial: 2660871
Drug: Amoxicillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (500 mg every 8 h)
Trial: 31781802
Drug: Adductor canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor canal block (ACB) with 0.3% ropivacaine 30 ml at mid-thigh adductor canal
Trial: 31781802
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block (FNB) with 0.3% ropivacaine 30 ml at the thigh root-femoral nerve
Trial: 20581700
Drug: L-arginine (ARG;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (ARG; 2 × 6 g·d)
Trial: 16599051
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg epinephrine + 4 ml hypertonic (3%) saline
Trial: 16599051
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg epinephrine + 4 ml normal (0.9%) saline
Trial: 10674281
Drug: GHB (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (25 mg/kg body weight p.o.)
Trial: 10674281
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg p.o. 2 h before GHB)
Trial: 9353508
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate 200 micrograms twice daily for 6 months
Trial: 2996816
Drug: Combined radio-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined radio- and chemotherapy (CCNU) after surgical resection
Trial: 30063658
Drug: Control (saline)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (saline) infusion
Trial: 27430558
Drug: Instruction about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instruction about treatment
Trial: 24262109
Drug: Intravenous acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetazolamide (5mg/kg) in patients undergoing retinal detachment surgery
Trial: 24262109
Drug: Intravenous acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acetazolamide (5mg/kg) in patients undergoing epiretinal membrane peeling
Trial: 15921774
Drug: Methylphenidate (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (therapeutic dose)
Trial: 11957163
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alfentanil and sufentanil (induction with alfentanil 15 microg/kg, maintenance with sufentanil 1 microg/kg/hr)
Trial: 10980844
Drug: Thrombolytic agents
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic agents (streptokinase, tissue-type plasminogen activator)
Trial: 10980844
Drug: New thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New thrombolytic agents
Trial: 2371814
Drug: Kennedy Ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kennedy Ligament Augmentation Device (LAD)
Trial: 2257866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg noscapine tablet
Trial: 2257866
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg noscapine tablet
Trial: 2257866
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg noscapine tablet
Trial: 2257866
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg noscapine solution
Trial: 2257866
Drug: Repeated administration
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated administration of noscapine tablets and solution
Trial: 7149946
Drug: Integrated behavioral‐physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated behavioral‐physical therapy treatment program including electromyographic feedback
Trial: 7149946
Drug: Standard exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard exercise physical therapy program
Trial: 25576687
Drug: Metoclopramide nasal
RxNorm normalized name: metoclopramide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide nasal spray 14 mg
Trial: 24142299
Drug: Rilpivirine/emtricitabine/tenofovir disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with standard meal (540 kcal, 21 g fat)
Trial: 24142299
Drug: Rilpivirine/emtricitabine/tenofovir disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) with light meal (390 kcal, 12 g fat)
Trial: 24142299
Drug: Rilpivirine/emtricitabine/tenofovir disoproxil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate (25/200/300 mg) under fasted conditions
Trial: 19382202
Drug: Topical Tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Tretinoin Chemoprevention
Trial: 15522370
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide injection (0.1 ml)
Trial: 19206044
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide injection
Trial: 15522370
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (subconjunctival saline)
Trial: 9248828
Drug: Treatment program
RxNorm normalized name: ZO Skin Health Acne Prevention Plus Treatment Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment program (12 weeks)
Trial: 16822114
Drug: Behavioral couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral couples therapy plus individual‐based treatment (BCT)
Trial: 16822114
Drug: Individual‐based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual‐based treatment only (IBT)
Trial: 16822114
Drug: Psychoeducational attention
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Psychoeducational attention control treatment (PACT)
Trial: 9081269
Drug: 7.6% carbohydrate-electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.6% carbohydrate-electrolyte (CE) solution
Trial: 29972213
Drug: Auraptene enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Auraptene enriched test juice (6.0 mg/day)
Trial: 24473387
Drug: Standard continuous
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard continuous blood purification with heparin anticoagulation
Trial: 22392567
Drug: Low plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low plasma concentration of DEX (0.04 ng/mL)
Trial: 22392567
Drug: High plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High plasma concentration of DEX (0.08 ng/mL)
Trial: 10587413
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium therapy for 4 weeks
Trial: 10587413
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium therapy (post-treatment)
Trial: 10587413
Drug: Montelukast sodium
RxNorm normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast sodium therapy
Trial: 8692528
Drug: IL-2 preoperative
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 preoperative therapy (18.10(6) IU/day subcutaneously for 3 consecutive days)
Trial: 8692528
Drug: IL-2 preoperative
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 preoperative therapy
Trial: 8692528
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no IL-2 preoperative therapy)
Trial: 1748776
Drug: Extradural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural buprenorphine 0.3 mg
Trial: 1748776
Drug: Extradural pentazocine
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural pentazocine 30 mg
Trial: 6632727
Drug: Dimethylbiguanide (DMB)
RxNorm normalized name: Dimethylbiguanid
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dimethylbiguanide (DMB) in doses of between 1 and 3 g
Trial: 28622048
Drug: TCZ‐SC 162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ‐SC 162 mg qw monotherapy
Trial: 28622048
Drug: TCZ‐SC 162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCZ‐SC 162 mg q2w monotherapy
Trial: 25315686
Drug: Powerade (Coca
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powerade (Coca Cola Ltd); 129 kJ.100 mL(‐1)
Trial: 25315686
Drug: Sustagen Sport
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustagen Sport (Nestle); 417 kJ.100 mL(‐1)
Trial: 25315686
Drug: Soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy milk (273 kJ.100 mL(‐1))
Trial: 25315686
Drug: Cow's milk
RxNorm normalized name: Cow's milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cow's milk (286 kJ.100 mL(‐1))
Trial: 19076245
Drug: Daily hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hygiene with a soft toothbrush and toothpaste (G1)
Trial: 19076245
Drug: Daily hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hygiene with a soft toothbrush and toothpaste plus immersion in sodium hypochlorite 0.5% for 20 min once a week (G2)
Trial: 17499654
Drug: Ketamine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.2 mg x kg(‐1) intravenous over 10 minutes)